Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05757869

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation

Sponsor: Bristol-Myers Squibb

Conditions Atrial Fibrillation

Interventions Apixaban Apixaban Placebo Milvexian Placebo

Updated 36 times since 2023 Last updated: Mar 12, 2026 Started: Apr 11, 2023 Primary completion: Oct 31, 2026 Completion: Oct 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05757869, this PHASE3 trial focuses on Atrial Fibrillation and remains ongoing. Sponsored by Bristol-Myers Squibb, it has been updated 36 times since 2023, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

36 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE3
Mar 2026 — Present [monthly]

Active Not Recruiting PHASE3
Feb 2026 — Present [monthly]

Active Not Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE3
Jan 2026 — Present [monthly]

Active Not Recruiting PHASE3

▶ Show 31 earlier versions

Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3
Oct 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE3
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Jun 2025 — Jul 2025 [monthly]

Active Not Recruiting PHASE3
May 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Apr 2025 — May 2025 [monthly]

Recruiting PHASE3
Mar 2025 — Apr 2025 [monthly]

Recruiting PHASE3
Feb 2025 — Mar 2025 [monthly]

Recruiting PHASE3
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE3
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE3
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE3
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE3
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Apr 2023 — Jun 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , A Coruña, Spain , Aalst, Belgium , Aarhus, Denmark , Adelaide, Australia , Afula, Israel , Afyonkarahisar, Turkey (Türkiye) , Aichi, Japan , Akron, United States , Alexander City, United States and 737 more locations